PAPER Li J, Liu C, Ang TF, Au R

Associations of Mid- and Late-Life Fasting Blood Glucose Levels With Dementia Risk Among Patients With Diabetes: Framingham Heart Study.

Eur J Neurol. 2025 Feb;32(2):e70062. PubMed.

PAPER Bergmann C, Mousaei K, Rizzoli SO, Tchumatchenko T

How energy determines spatial localisation and copy number of molecules in neurons.

Nat Commun. 2025 Feb 7;16(1):1424. PubMed.

PAPER Huang Q

The U.S dementia belt: Commentary on "Alzheimer's disease and related dementia among Medicare beneficiaries aged ≥ 65 years in rural America, by census region and select demographic characteristics: 2020".

J Rural Health. 2025 Jan;41(1):e70000. PubMed.

PAPER Thomas EV, Han C, Kim WJ, Asress S, Li Y, Taylor JA, Gearing M, Fournier CN, McEachin ZT, Seyfried NT, Glass JD

ALS plasma biomarkers reveal neurofilament and pTau correlate with disease onset and progression.

Ann Clin Transl Neurol. 2025 Feb 6; Epub 2025 Feb 6 PubMed.

PAPER Baiardi S, Parchi P

Perspectives Toward the Development of Quantitative Seed Amplification Assays for α-Synuclein.

Neurology. 2025 Mar 11;104(5):e213384. Epub 2025 Feb 6 PubMed.

PAPER Coughlin DG, Shifflett B, Farris CM, Ma Y, Galasko D, Edland SD, Mollenhauer B, Brumm MC, Poston KL, Marek K, Siderowf AD, Soto C, Concha-Marambio L, as the Investigators of the Parkinson's Progression Marker Initiative

α-Synuclein Seed Amplification Assay Amplification Parameters and the Risk of Progression in Prodromal Parkinson Disease.

Neurology. 2025 Mar 11;104(5):e210279. Epub 2025 Feb 6 PubMed.

PAPER Chemla A, Arena G, Sacripanti G, Barmpa K, Zagare A, Garcia P, Gorgogietas V, Antony P, Ohnmacht J, Baron A, Jung J, Lind-Holm Mogensen F, Michelucci A, Marzesco AM, Buttini M, Schmidt T, Grünewald A, Schwamborn JC, Krüger R, Saraiva C

Parkinson's disease mutant Miro1 causes mitochondrial dysfunction and dopaminergic neuron loss.

Brain. 2025 Feb 6; Epub 2025 Feb 6 PubMed.

PAPER Mielke MM, Evans JK, Neiberg RH, Molina-Henry DP, Marcovina SM, Johnson KC, Carmichael OT, Rapp SR, Sachs BC, Ding J, Shappell HM, Luchsinger JA, Espeland MA, Hayden KM

Alzheimer Disease Blood Biomarkers and Cognition Among Individuals With Diabetes and Overweight or Obesity.

JAMA Netw Open. 2025 Feb 3;8(2):e2458149. PubMed.

PAPER Yao C, Shan Y, Cui B, Chen Z, Bi S, Wang T, Yan S, Lu J

Hyperconnectivity and Connectome Gradient Dysfunction of Cerebello-Thalamo-Cortical Circuitry in Alzheimer's Disease Spectrum Disorders.

Cerebellum. 2025 Feb 6;24(2):43. PubMed.

PAPER Wang Q, Wang S, Cao S, Wang Q, Wei Y, Li Y, Wang Y, Li Y, Qin W, Quan M, Jia J

A Novel Missense Variant in SORBS2 Is Causative With Familial Alzheimer's Disease.

CNS Neurosci Ther. 2025 Feb;31(2):e70256. PubMed.

PAPER Wolner SH, Gleerup HS, Musaeus CS, Høgh P, Ashton NJ, Brinkmalm A, Nilsson J, Grötschel L, Zetterberg H, Blennow K, Hasselbalch SG, Walls AB, Simonsen AH

Synaptosomal-Associated Protein 25 kDA (SNAP-25) Levels in Cerebrospinal Fluid: Implications for Alzheimer's Disease Diagnosis and Monitoring.

Synapse. 2025 Mar;79(2):e70010. PubMed.

PAPER Michaelian JC, Rowe CC, Kurrle SE, Pond CD, Woodward M, Naismith SL

Is Australia ready for the rollout of amyloid-targeting therapies for Alzheimer's disease? Results from a national survey characterising current infrastructure capability, workforce and training needs of memory and cognition clinics.

Intern Med J. 2025 Feb 6; Epub 2025 Feb 6 PubMed.

PAPER Zhang R, Ding N, Feng X, Liao W

The gut microbiome, immune modulation, and cognitive decline: insights on the gut-brain axis.

Front Immunol. 2025;16:1529958. Epub 2025 Jan 22 PubMed.

PAPER Putcha D, Katsumi Y, Touroutoglou A, Eloyan A, Taurone A, Thangarajah M, Aisen P, Dage JL, Foroud T, Jack CR Jr, Kramer JH, Nudelman KN, Raman R, Vemuri P, Atri A, Day GS, Duara R, Graff-Radford NR, Grant IM, Honig LS, Johnson EC, Jones DT, Masdeu JC, Mendez MF, Musiek E, Onyike CU, Riddle M, Rogalski E, Salloway S, Sha S, Turner RS, Wingo TS, Wolk DA, Womack K, Carrillo MC, Rabinovici GD, Dickerson BC, Apostolova LG, Hammers DB, LEADS Consortium

Heterogeneous clinical phenotypes of sporadic early-onset Alzheimer's disease: a neuropsychological data-driven approach.

Alzheimers Res Ther. 2025 Feb 6;17(1):38. PubMed.

PAPER Hussain F, Tahir A, Rehman HM, Wu Y, Shah M, Rashid U

Promising thiazolidinedione-thiazole based multi-target and neuroprotective hybrids for Alzheimer's disease: Design, synthesis, in-vitro, in-vivo and in-silico studies.

Eur J Med Chem. 2025 Feb 3;287:117327. Epub 2025 Feb 3 PubMed.